BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250123T190000
DTEND;TZID=Africa/Nairobi:20250123T203000
DTSTAMP:20260424T003535
CREATED:20250611T183601Z
LAST-MODIFIED:20250622T142307Z
UID:38855-1737658800-1737664200@kesho-kenya.org
SUMMARY:Cervical Cancer Care
DESCRIPTION:Advanced Ovarian Cancer \nModerator: Prof Rose J. Kosgei \nSpeakers & Topics: \n\nProf Omenge Orang’o: Management of Epithelial Ovarian Cancer\nDr Peter Oyiro: PARP Inhibitors in Ovarian Cancer\nDr Charles Muteshi: Fertility Preservation in Ovarian Cancer\n\nEpidemiology and Diagnosis (Prof. Omenge Oran’go) \n– Ovarian cancer remains a significant cause of cancer mortality among women due to its asymptomatic nature in early stages.\n– Kenya sees many cases diagnosed at advanced stages (III/IV)\, primarily due to non-specific symptoms and lack of screening.\n– Important to understand pelvic anatomy and tumor spread patterns for accurate diagnosis and surgical planning. \nFertility Preservation in Ovarian Cancer (Dr. Charles Muteshi) \n– Fertility-sparing surgery should be considered in selected early-stage epithelial ovarian cancers (Stage I).\n– Discussion on embryo/oocyte cryopreservation for patients undergoing gonadotoxic treatment.\n– Emphasized need for multidisciplinary counseling and prompt fertility consultations to ensure oncologic safety and reproductive potential. \nRole of PARP Inhibitors (Dr. Peter Oyiro) \n– PARP inhibitors like Olaparib offer significant benefits in BRCA-mutated and homologous recombination-deficient (HRD) ovarian cancers.\n– SOLO-1 and SOLO-2 studies demonstrated prolonged progression-free survival and delayed recurrence in both frontline and maintenance settings.\n– 7-year follow-up data show sustained benefit\, with over 48% progression-free survival in Olaparib arms.\n– Low incidence of serious adverse events\, with anemia\, fatigue\, and nausea as the most common.\n– Highlighted integration into Kenya Cancer Treatment Guidelines and importance of HRD testing.
URL:https://kesho-kenya.org/event/cervical-cancer-care/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/06/Cervical-Cancer-scaled-e1749667096838.jpg
END:VEVENT
END:VCALENDAR